Although our identification of increased Atf2 expression aligns with similar findings from human patients with Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, it contrasts with a previous study demonstrating that mice treated with doxorubicin-based multiagent protocols had significant downregulation of brain Atf2 [8,67]. This evidence concerns the gene ATF2 and Huntington disease.